Glückstein Marie-Isabelle, Dintner Sebastian, Miller Silvia, Vlasenko Dmytro, Schenkirsch Gerhard, Agaimy Abbas, Märkl Bruno, Grosser Bianca
General Pathology and Molecular Diagnostics, Medical Faculty, University of Augsburg, 86159 Augsburg, Germany.
General, Visceral, and Transplantation Surgery, Medical Faculty, University of Augsburg, 86159 Augsburg, Germany.
Diagnostics (Basel). 2022 Feb 7;12(2):429. doi: 10.3390/diagnostics12020429.
ALK, NUT, and TRK are rare molecular aberrations that are pathognomonic for specific rare tumors. In low frequencies, however, they are found in a wide range of other tumor entities. This study aimed to investigate the frequency, association with clinicopathological characteristics, and prognosis of the immunohistochemical expressions of ALK, NUT, and TRK in 477 adenocarcinomas of the stomach and gastroesophageal junction. Seven cases (1.5%) showed an expression of TRK. In NGS, no fusion was confirmed. No case with ALK or NUT expression was detected. , and expression does not seem to play an important role in gastric carcinomas.
间变性淋巴瘤激酶（ALK）、核仁蛋白（NUT）和原肌球蛋白受体激酶（TRK）是特定罕见肿瘤所特有的罕见分子异常。然而，在低频率情况下，它们也存在于多种其他肿瘤实体中。本研究旨在调查ALK、NUT和TRK免疫组化表达在477例胃腺癌和胃食管交界腺癌中的频率、与临床病理特征的相关性及预后情况。7例（1.5%）显示有TRK表达。在二代测序（NGS）中，未确认有融合情况。未检测到有ALK或NUT表达的病例。ALK、NUT和TRK表达似乎在胃癌中不起重要作用。
